E2 ModerateModerate confidencePEM ✗Machine draft
Genome-epigenome interactions associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Herrera, Santiago, de Vega, Wilfred C, Ashbrook, David et al. · Epigenetics · 2018 · DOI
Quick Summary
This study examined how genes and chemical switches on genes (called methylation) work together in ME/CFS patients. Researchers compared immune cells from people with ME/CFS to healthy people, looking at hundreds of thousands of genetic markers and chemical modifications. They found that certain chemical switches on genes involved in immune function and energy production are different in ME/CFS patients, and these differences are connected to a person's genetic makeup.
Why It Matters
This study provides evidence that ME/CFS involves complex interactions between inherited genetic factors and acquired epigenetic changes, moving beyond single-factor explanations. Understanding these interactions may help identify biomarkers for diagnosis and potential therapeutic targets in immune and metabolic pathways.
Observed Findings
- Significant associations between DNA methylation patterns at multiple CpG loci in T-lymphocytes and ME/CFS status
- DNA methylation anomalies located near genes involved in immune function and cellular metabolism
- Correlations between specific genotypes and methylation modifications in ME/CFS patients
- Epigenetic variation distinguishable between ME/CFS cases and healthy controls
Inferred Conclusions
- Genetic and epigenetic interactions play a role in ME/CFS disease mechanisms
- Immune function and metabolic pathways are dysregulated at both genetic and epigenetic levels in ME/CFS
- A person's genetic background influences how their genes are chemically modified in ME/CFS
Remaining Questions
- Do epigenetic changes occur before disease onset or are they consequences of having ME/CFS?
- How do the observed epigenetic changes in T-lymphocytes affect immune cell function in ME/CFS?
- Are similar genome-epigenome interactions present in other immune cell types and tissues?
- Can these genetic and epigenetic markers be used to predict disease progression or treatment response?
What This Study Does Not Prove
This study does not prove that genetic or epigenetic differences cause ME/CFS—it only shows associations. The cross-sectional design cannot determine whether methylation changes precede disease onset or result from having the illness. The findings in T-lymphocytes may not reflect changes in other cell types or tissues.